EMA group drafts guidelines for copycat versions of interferon beta; Capstone Therapeutics hits brakes on key program;

@FierceBiotech: Quintiles to hire 500 for new BPO hub in China, where the giant CRO has a growing presence. Story | Follow @FierceBiotech

@JohnCFierce: Trounson on the effect of Geron ESC exit: "a very strong negative influence internationally." Item | Follow @JohnCFierce

@RyanMFierce: Sanofi's Viehbacher to FDA: We need clear risk-benefit guidance to invest in primary care drugs. Article | Follow @RyanMFierce

@MarkHFierce: Scientists are up in arms in CA about plunging state funding support for research. More | Follow @MarkHFierce

@FierceMedDev: Covidien CEO Elected Chairman of the Board. Release | Follow @FierceMedDev

> The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued draft guidance on a path for developing copycat versions of biotech drugs, called biosimilars, which contain the MS treatment interferon beta. A public comment period ends May 31. Report

> Two groups are interested in snapping up drug developer Geron's embryonic stem cell program, which the California company dumped last year over financial concerns. Item

> Capstone Therapeutics hit the brakes on development of its lead drug against dermal scarring, AZX100, in an effort to preserve cash at the struggling company. Release

> Seattle-based Cell Therapeutics ($CTIC) said today the CHMP could soon decide on whether to stamp an approval on Pixuvri for treating adults with multiple relapsed or refractory aggressive non-Hodgkin's B cell lymphomas. Release

Pharma News

@FiercePharma: Why do more than half of doctors oppose mandatory HPV vax? Check the latest from . Survey | Follow @FiercePharma

> Merck to pay up to $37M in Canadian Vioxx case. News

> Can AstraZeneca continue to swear off major M&A? More

> Foreign pharma deals snag on new Indian rules. Article

> New death reports prompt EMA review of Gilenya. Story

> Yaz plaintiffs ask judge to weigh alleged FDA conflicts. Item

And Finally... Doctors have taken a step toward refining the rules of the road for diagnosing autism. Report

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.